Scribe Therapeutics SCTX
NASDAQ SCTX
$16.86 -0.50 (-2.88%)
At close: Nov 11, 2026 · 4:00 PM EST

Scribe Therapeutics (SCTX) Current Deferred Revenue (2024 - 2026)

Analysis

Scribe Therapeutics (SCTX) Current Deferred Revenue (2024 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Scribe Therapeutics 43.14 Mn 143,663.76 -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 27.48 Mn
Mar 31, 2026 28.33 Mn
Dec 31, 2025 21.09 Mn
Dec 31, 2024 23.41 Mn
API Access

Scribe Therapeutics Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=SCTX&period=max&api_key=YOUR_API_KEY